Clinical Trial Update: A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6 [Phase 3]

View source ↗

Summary

Phase 3 study of peginterferon alfa-2a plus ribavirin in early non-responder participants with chronic hepatitis C (genotypes 1, 4, 5, and 6) has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 3 | Status: TERMINATED